Crossmark Global Holdings Inc. Grows Position in Bristol Myers Squibb Company (NYSE:BMY)

Crossmark Global Holdings Inc. grew its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 13.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 216,452 shares of the biopharmaceutical company's stock after buying an additional 25,638 shares during the period. Crossmark Global Holdings Inc.'s holdings in Bristol Myers Squibb were worth $13,201,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. King Wealth Management Group grew its stake in shares of Bristol Myers Squibb by 2.6% in the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock worth $413,000 after buying an additional 182 shares in the last quarter. Thoroughbred Financial Services LLC lifted its holdings in shares of Bristol Myers Squibb by 1.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after acquiring an additional 190 shares during the last quarter. Marcum Wealth LLC lifted its holdings in shares of Bristol Myers Squibb by 1.0% in the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after acquiring an additional 193 shares during the last quarter. Leelyn Smith LLC lifted its holdings in shares of Bristol Myers Squibb by 0.5% in the 4th quarter. Leelyn Smith LLC now owns 47,699 shares of the biopharmaceutical company's stock worth $2,698,000 after acquiring an additional 215 shares during the last quarter. Finally, Heron Bay Capital Management lifted its holdings in shares of Bristol Myers Squibb by 2.1% in the 4th quarter. Heron Bay Capital Management now owns 10,795 shares of the biopharmaceutical company's stock worth $611,000 after acquiring an additional 220 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 2.3%

Shares of NYSE:BMY traded up $1.08 during trading hours on Tuesday, hitting $47.57. The company's stock had a trading volume of 2,404,283 shares, compared to its average volume of 12,833,747. Bristol Myers Squibb Company has a 52 week low of $39.50 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The company has a market capitalization of $96.81 billion, a price-to-earnings ratio of 17.81, a P/E/G ratio of 1.39 and a beta of 0.36. The firm's fifty day moving average price is $47.69 and its 200 day moving average price is $53.50.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the firm earned ($4.40) EPS. The company's quarterly revenue was down 5.6% compared to the same quarter last year. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.21%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 92.88%.

Insider Activity

In other news, EVP Samit Hirawat acquired 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The shares were purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BMY has been the subject of several analyst reports. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. UBS Group lowered their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. Finally, Jefferies Financial Group decreased their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.